Enpro (NPO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for April 30, 2025, with four key proposals: election of ten directors, advisory vote on executive compensation, approval of amended 2020 Equity Compensation Plan, and ratification of PricewaterhouseCoopers LLP as auditor.
Company highlights include $1.0 billion in revenue, 3,500 employees, and a focus on high-margin growth, operational excellence, and sustainability.
Shareholder engagement is emphasized, with regular outreach to major investors and alignment of governance and compensation practices with shareholder interests.
Voting matters and shareholder proposals
Shareholders will vote on: (1) election of ten directors, (2) advisory approval of executive compensation, (3) approval of the amended and restated 2020 Equity Compensation Plan, and (4) ratification of PricewaterhouseCoopers LLP as independent auditor.
Board recommends voting “For” all proposals.
Shareholders can vote by Internet, phone, mail, or in person.
Board of directors and corporate governance
Board consists of ten nominees, nine of whom are independent; diversity includes three women and one racially/ethnically diverse member.
Board committees: Executive, Audit and Risk Management, Compensation and Human Resources, and Nominating and Corporate Governance.
Annual board, committee, and individual director evaluations are conducted.
Directors are required to own company stock; stringent stock ownership and anti-hedging/pledging policies are in place.
Board refreshment has added five new directors in the past five years.
Latest events from Enpro
- Strong 2025 results and 2026 growth outlook driven by high-margin tech focus and strategic acquisitions.NPO
Investor presentation18 Feb 2026 - Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPO
Q4 202518 Feb 2026 - Adjusted EBITDA rose 14% to $74.0M as Sealing Technologies offset semiconductor weakness.NPO
Q2 20242 Feb 2026 - Q3 2024 sales and margins rose, but guidance was cut on semiconductor and OEM weakness.NPO
Q3 202416 Jan 2026 - Portfolio transformation and operational excellence drive strong margins and growth outlook.NPO
Sidoti Small-Cap Virtual Investor Conference11 Jan 2026 - Adjusted EBITDA rose 7.1% in 2024, with 2025 guidance signaling further growth.NPO
Q4 202423 Dec 2025 - Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPO
Gabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025 - Director Adele M. Gulfo joins NewAmsterdam Pharma's board ahead of her re-election vote.NPO
Proxy Filing1 Dec 2025 - Director Ronald C. Keating joins Hayward Holdings' board; biography updated for 2025 vote.NPO
Proxy Filing1 Dec 2025